Piper Sandler Reiterates Overweight on Immunic, Maintains $28 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Yasmeen Rahimi has reiterated an Overweight rating on Immunic (NASDAQ:IMUX) and maintained a $28 price target.

July 16, 2024 | 3:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler analyst Yasmeen Rahimi has reiterated an Overweight rating on Immunic (NASDAQ:IMUX) and maintained a $28 price target.
The reiteration of an Overweight rating and a maintained price target of $28 by Piper Sandler is a positive signal for investors, suggesting confidence in the company's future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100